关键词: 主编风采, 江亚伍, 海外副主编

Abstract:

Prof. Ah-Ng Tony Kong is Distinguished Professor, Glaxo Endowed Chair in Pharmaceutics and Director of the Graduate Program in Pharmaceutical Sciences. He is Co-Leader of the Carcinogenesis and Cancer Prevention Program and Co-Director of the PK-PD facility Core at the Cancer Institute of New Jersey (CINJ). He serves on the Dean’s Budget and Policy (Executive) Committee, Ernest Mario School of Pharmacy since 2003. At the University level, he served on the Committee on Academic Planning and Review (CAPR; an advisory committee to the Executive Vice President of Academic Affairs, equivalent to chancellor) from 2007–2012. He was appointed the Interim Chair of PresidentCommittee on Academic Planning and Review (advisory committee to the Executive Vice President of Academic Affairs of Rutgers, and Interim Chancellor of Rutgers New Brunswick Campus) in 2012–2013. He continues to serve on the Committee on Academic Planning and Review, 2012–present. He is member of 13 editorial boards of international journals, oversea Editor-in-Chief of Journal of Chinese Pharmaceutical Sciencesfrom 2013, editor of Pharmaceutical Research (2004–present), and the editor in-chief of Current Pharmacology Reports (Springer; epub journal–first issue to appear January 2015). He has published more than 200 original research, review articles and book chapters in pharmacokinetics, pharmacodynamics, PK-PD modeling, drug metabolism, pharmacogenomics, cellular signaling, Nrf₂-mediated anti-oxidative stress and anti-inflammatory responses, and cancer chemoprevention by dietary phytochemicals. He has been supported by the National Institutes of Health continuously since 1993, totaling more than $20 million. He has continued to serve on numerous NIH panels since 1998. He is the Editor-in-Chief,Current Pharmacological Reports (Springer, 2013), an Editor of Pharmaceutical Research, Associate Editor of Molecular Carcinogenesis and Life Sciences and member of Editorial Board of nine scientific journals such as Cancer Prevention Research, Carcinogenesis and Biopharmaceutics and Drug Disposition. He has directed the research of more than 40 doctoral students, postdoctoral associates, and visiting scholars. 

Key words: Editor profile, Ah-Ng Tony Kong, Oversea Editor-in-Chief